Clinical Trials in Germany

• An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis Ended
  2022-502994-40-00 Phase II Rheumatoid Arthritis Eli Lilly & Co.
• A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in p… Ended
  2022-502821-16-00 Phase II Knee Osteoarthritis Novartis Pharma AG
• A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patie… Ended
  2022-502828-42-00 Phase II Idiopathic Pulmonary Fibrosis Genentech Inc.
• A study to understand how well DC806 works and how safe it is in participants with plaque psoriasis Ended
  2022-502249-90-00 Phase II Plaque Psoriasis DICE Therapeutics Inc.
• SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of… Ended
  2022-502697-16-00 Phase III Neurotrophic Keratopathy Regentree LLC
• A study to test how well different doses of BI 1584862 are tolerated by healthy men Ended
  2023-503541-54-00 Phase I (Other) Healthy volunteer trial Boehringer Ingelheim International GmbH
• A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and… Ended
  2022-502382-25-00 Phase II Heart Failure and Pulmonary Hypertension due to Left Heart D… AstraZeneca AB
• INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Stu… Ended
  2022-501661-47-00 Phase II Myelofibrosis ; postlung transplant (BOS); chronic graft-ver… Incyte Corp.
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Ended
  2023-505567-37-00 Phase II/III Moderate-to-severe allergic rhinitis / rhinoconjunctivitis d… ROXALL Medizin GmbH
• A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and… Ended
  2023-504450-35-00 Phase I Plaque psoriasis Otsuka Pharmaceutical Development & Commercialization Inc.
• A three part randomized, double-blind, placebo-controlled, parallel group SAD and MD clinical study to evaluate the safety, tolerability and… Ended
  2023-507203-55-00 Phase I Pseudomonas colonization Charite Research Organisation GmbH
• A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 … Ended
  2022-502866-25-00 Phase I Sepsis associated disseminated intravascular coagulation Bayer AG
• A two-part, open-label study to assess the pharmacokinetics, pharmacodynamics and safety of single doses of inhaled and intravenously admini… Ended
  2022-503037-63-00 Phase I (Other) Phase I, Clinical trial in healthy males and females intende… Aspiair GmbH
• EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Met… Ended
  2024-515407-19-00 Phase III Metastatic pancreatic ductal adenocarcinoma (mPDAC) Novocure GmbH
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary… Ended
  2022-500746-16-00 Phase II Geographic Atrophy Janssen - Cilag International
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended
  2022-502000-73-00 Phase III Focal Onset Seizures Xenon Pharmaceuticals Inc.
• A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.78… Ended
  2022-502045-10-00 Phase II Atopic dermatitis Bioprojet Pharma
• APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with… Ended
  2023-503244-14-00 Phase I (FiH) Relapsed or Refractory Acute Myeloid Leukemia (AML) Aptose Biosciences Inc.
• A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended
  2022-501097-19-00 Phase II dermatomyositis Galapagos
• A Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) in Subjects with Fuchs Dystrophy Ended
  2022-502643-35-00 Phase III Fuchs Endothelial Corneal Dystrophy Kowa Research Institute Inc.
• A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy p… Ended
  2023-503949-65-00 Phase I (Other) Type 2 Diabetes Novo Nordisk A/S
• An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerabil… Ended
  2022-502952-30-00 Phase I (Other) Healthy Adult Participants Janssen - Cilag International
• The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr… Ended
  2022-500449-26-00 Phase IV Type 2 diabetes mellitus (T2DM) University Medical Center Utrecht
• A study in healthy men to test how itraconazole influences the amount of BI 1815368 in the blood Ended
  2023-503783-16-00 Phase I (Other) Healthy Boehringer Ingelheim International GmbH

Showing 3,289–3,312 of 3,929 trials